Joanne M. Hackett, Ph.D.
INTERIM CHIEF EXECUTIVE OFFICER
Dr. Joanne M. Hackett is the Head of Genomic and Precision Medicine at IQVIA. IQVIA is a world leader in using data, technology, advanced analytics, and expertise to help customers drive healthcare forward. From 2017 to 2020 Dr. Hackett served as Chief Commercial Officer of Genomics England, where she engaged industry, academia and the clinical community to achieve the goal of sequencing genomes of patients and families of patients with rare diseases, and patients with common cancers. Genomics England is owned by the Department of Health and Social Care in the United Kingdom.
During 2016 and 2017 Dr. Hackett served as Chief Commercial Officer and Interim Chief Executive Officer of Precision Medicine Catapult, which was established in the United Kingdom with the goal of developing, delivering and commercializing precision medicine. Dr. Hackett served as Director of Commercial Development for UCLPartners in London, England from 2013 – 2016. UCLPartners is focused on co-creating, testing and implementing innovative healthcare solutions with its academic and healthcare partners, and fostering the wider spread and adoption of those solutions. Previously, she served as Chief Operating Officer and Research Lead at Cambridge University Health Partners, and she has held other positions in the biomedical industry and in academia, including as a research scientist, and she has served on a number of advisory committees and advisory boards in the biomedical and healthcare fields.
Dr. Hackett holds a PhD in Molecular Genetics from the University of New Brunswick.
Our Team
Joanne M. Hackett, Ph.D.
INTERIM CHIEF EXECUTIVE OFFICER
Dr. Joanne M. Hackett is the Head of Genomic and Precision Medicine at IQVIA. IQVIA is a world leader in using data, technology, advanced analytics, and expertise to help customers drive healthcare forward. From 2017 to 2020 Dr. Hackett served as Chief Commercial Officer of Genomics England, where she engaged industry, academia and the clinical community to achieve the goal of sequencing genomes of patients and families of patients with rare diseases, and patients with common cancers. Genomics England is owned by the Department of Health and Social Care in the United Kingdom.
During 2016 and 2017 Dr. Hackett served as Chief Commercial Officer and Interim Chief Executive Officer of Precision Medicine Catapult, which was established in the United Kingdom with the goal of developing, delivering and commercializing precision medicine. Dr. Hackett served as Director of Commercial Development for UCLPartners in London, England from 2013 – 2016. UCLPartners is focused on co-creating, testing and implementing innovative healthcare solutions with its academic and healthcare partners, and fostering the wider spread and adoption of those solutions. Previously, she served as Chief Operating Officer and Research Lead at Cambridge University Health Partners, and she has held other positions in the biomedical industry and in academia, including as a research scientist, and she has served on a number of advisory committees and advisory boards in the biomedical and healthcare fields.
Dr. Hackett holds a PhD in Molecular Genetics from the University of New Brunswick.
Andrea E. Park, CPA (inactive)
CHIEF FINANCIAL OFFICER
Andrea E. Park, CPA (inactive) was appointed as Chief Financial Officer of AgeX Therapeutics, Inc. in May 2020. Prior to that, Ms. Park served as the company’s VP of Finance and Controller since October 2019. As CFO, Ms. Park is responsible for all of the company’s financial functions including accounting, internal and external audits, tax, and treasury. Ms. Park’s career spans over 24 years of public accounting and finance experience. Before joining AgeX, Ms. Park served as VP of Finance and Controller from June 2016 to September 2019 and as Corporate Controller from August 2009 to June 2016 for Lineage Cell Therapeutics, Inc. (NYSE American: LCTX). While at Lineage, Ms. Park was directly involved in the accounting and financial reporting of the public spin off and eventually the deconsolidation of three of its then subsidiaries including Asterias Biotherapeutics, Inc., Oncocyte Corporate and AgeX. Earlier in her career she has worked in the audit and assurance practice at Deloitte. Ms. Park has a B.A. in Business Economics with Concentration in Accounting from the University of California, Santa Barbara.
Hal Sternberg, Ph.D.
VP, RESEARCH
Hal Sternberg, Ph.D., is Vice President of Research. Prior to joining AgeX, he was BioTime’s Vice President of Research for over 25 years and was one of the company’s co-founders. Before that, Dr. Sternberg held various positions at the University of California at Berkeley from 1982 to 1988, where he worked on Alzheimer’s Disease. Dr. Sternberg was instrumental in the development of the medical product Hextend, bringing it through regulatory approval as a blood plasma volume expander for treating blood loss. Dr. Sternberg received his M.S. in Chemistry (1979) and Ph.D. in Biochemistry (1982) from the University of Maryland.
Judith Segall
DIRECTOR – ADMINISTRATION
CORPORATE SECRETARY
Judith Segall is our Director of Administration and Corporate Secretary. Prior to joining AgeX, Ms. Segall was the Vice President of Administration of BioTime, Inc. As one of BioTime’s co-founders in 1990, she served on the BioTime Board of Directors and as an executive for over 25 years. Ms. Segall received her B.S. in Nutrition and Clinical Dietetics from the University of California at Berkeley.
Andrea E. Park, CPA (inactive)
CHIEF FINANCIAL OFFICER
Andrea E. Park, CPA (inactive) was appointed as Chief Financial Officer of AgeX Therapeutics, Inc. in May 2020. Prior to that, Ms. Park served as the company’s VP of Finance and Controller since October 2019. As CFO, Ms. Park is responsible for all of the company’s financial functions including accounting, internal and external audits, tax, and treasury. Ms. Park’s career spans over 24 years of public accounting and finance experience. Before joining AgeX, Ms. Park served as VP of Finance and Controller from June 2016 to September 2019 and as Corporate Controller from August 2009 to June 2016 for Lineage Cell Therapeutics, Inc. (NYSE American: LCTX). While at Lineage, Ms. Park was directly involved in the accounting and financial reporting of the public spin off and eventually the deconsolidation of three of its then subsidiaries including Asterias Biotherapeutics, Inc., Oncocyte Corporate and AgeX. Earlier in her career she has worked in the audit and assurance practice at Deloitte. Ms. Park has a B.A. in Business Economics with Concentration in Accounting from the University of California, Santa Barbara.
Hal Sternberg, Ph.D.
VP, RESEARCH
Hal Sternberg, Ph.D., is Vice President of Research. Prior to joining AgeX, he was BioTime’s Vice President of Research for over 25 years and was one of the company’s co-founders. Before that, Dr. Sternberg held various positions at the University of California at Berkeley from 1982 to 1988, where he worked on Alzheimer’s Disease. Dr. Sternberg was instrumental in the development of the medical product Hextend, bringing it through regulatory approval as a blood plasma volume expander for treating blood loss. Dr. Sternberg received his M.S. in Chemistry (1979) and Ph.D. in Biochemistry (1982) from the University of Maryland.
Judith Segall
DIRECTOR – ADMINISTRATION
CORPORATE SECRETARY
Judith Segall is our Director of Administration and Corporate Secretary. Prior to joining AgeX, Ms. Segall was the Vice President of Administration of BioTime, Inc. As one of BioTime’s co-founders in 1990, she served on the BioTime Board of Directors and as an executive for over 25 years. Ms. Segall received her B.S. in Nutrition and Clinical Dietetics from the University of California at Berkeley.
Board of Directors
Joanne M. Hackett, Ph.D.
Chairperson
Dr. Joanne M. Hackett is the Head of Genomic and Precision Medicine at IQVIA. IQVIA is a world leader in using data, technology, advanced analytics, and expertise to help customers drive healthcare forward. From 2017 to 2020 Dr. Hackett served as Chief Commercial Officer of Genomics England, where she engaged industry, academia and the clinical community to achieve the goal of sequencing genomes of patients and families of patients with rare diseases, and patients with common cancers. Genomics England is owned by the Department of Health and Social Care in the United Kingdom.
During 2016 and 2017 Dr. Hackett served as Chief Commercial Officer and Interim Chief Executive Officer of Precision Medicine Catapult, which was established in the United Kingdom with the goal of developing, delivering and commercializing precision medicine. Dr. Hackett served as Director of Commercial Development for UCLPartners in London, England from 2013 – 2016. UCLPartners is focused on co-creating, testing and implementing innovative healthcare solutions with its academic and healthcare partners, and fostering the wider spread and adoption of those solutions. Previously, she served as Chief Operating Officer and Research Lead at Cambridge University Health Partners, and she has held other positions in the biomedical industry and in academia, including as a research scientist, and she has served on a number of advisory committees and advisory boards in the biomedical and healthcare fields.
Dr. Hackett holds a PhD in Molecular Genetics from the University of New Brunswick.
Gregory Bailey, M.D.
Gregory Bailey, M.D., is Executive Chairman of Juvenescence Limited, a company that develops therapeutics, so people can have healthier, longer lives.
Dr. Bailey has been founding and financing life science companies since 1995. Some of these companies have traded on NASDAQ, AIM, AMEX and NYSE, reaching over $18 billion in market capitalization. He co-founded Ascent Health Care in 1995, which was sold to Stryker for $525 million in 2009. In 2004, he was the initial financier and a board member of Medivation, Inc. (MDVN: NASDAQ). It was ultimately acquired by Pfizer in September 2016 for $14.3 billion. In January 2014, Dr. Bailey along with his partners capitalized Biohaven through Portage Biotech with $3.5 million, subsequently adding a further $3.5 million over the next two years. Biohaven went public May 2017 on NYSE. Portage was the major shareholder in Biohaven until it did a dividend of $210 million of Biohaven shares to Portage shareholders. Dr. Bailey remains a major shareholder of Biohaven, which has a market cap of a little over $1.5 billion.
Along with AgeX, Gregory Bailey currently sits on the Board of Directors of three public companies: Portage Biotech, Inc. (PTGEF:OTC); SalvaRx PLC. (SALV.L:AIM); and Biohaven Pharmaceutical Holding Company Ltd. (BHVN:NYSE).
Dr. Bailey received his medical doctorate from the University of Western Ontario.
Steven Mintz
Steven Mintz has been a self-employed financial consultant since 1998 serving both private individuals and companies, as well as public companies in a variety of industries including mining, oil and gas, real estate and investment strategies. He is currently President of St. Germain Capital Corp., a private consulting and investment firm. He is also a principal and CFO of the Minkids Group, a family investment and development company. Mr. Mintz is currently a director of Portage Biotech, Inc., a clinical-stage immuno-oncology company advancing multi-targeted therapies for cancer. Mr. Mintz previously served as a director of IM Cannabis (formerly Navasota Resources). Mr. Mintz graduated from the University of Toronto in 1989 and obtained his C.A. designation in June of 1992.
Jean-Christophe Renondin, M.D.
Dr. Renondin is Managing Partner at Vesalius Biocapital, a venture capital firm. From 2015 to 2022, Dr. Renondin served as Senior Healthcare Manager at the Sovereign Fund of Oman where he implemented investment strategy and pursued investment opportunities in North America, Europe and Asia. Dr. Renondin has served in management roles at a number of healthcare and investment firms, including serving for five years as managing director of Bryan Garnier & Co. Dr. Renondin served as a director of Cognate Bioservices Limited, a company in the business of contract development and manufacturing, specializing in cell and cell-mediated gene therapy products, which is now owned by Charles River Laboratories International, as a director of Juvenescence Limited from March 2020 until June 2023, and as a director of Viscogliosi Brothers Acquisition Corp. Dr. Renondin received an MBA degree from the Tuck School of Business at Dartmouth University and an MD degree from Universite Paris Cite.